Fresenius Kabi

ECU students at PharmaFest seek opportunities in the pharmaceutical industry, which offers diverse career paths beyond biology and chemistry, including engineering, IT, and finance. The event, supported by ECU’s Eastern Region Pharma Center and the North Carolina Biotechnology Center, aims to connect students with potential employers and internships.

Teva Pharmaceuticals and mAbxience expand strategic partnership with a new global licensing agreement for an anti PD-1 oncology biosimilar candidate, with mAbxience leading development and production and Teva managing regulatory approvals and commercialization.

Tulisokibart maintained clinical and endoscopic improvements in IBD patients through week 50 in phase II trial extensions, with 48% of ulcerative colitis patients and 56% of Crohn's disease patients achieving clinical remission. The drug was well-tolerated with no identified safety signals.

FDA approves Imuldosa (ustekinumab-srlf), a biosimilar to Stelara, for treating psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis in both adults and pediatric patients. Imuldosa, initially developed as DMB-3115, demonstrated similar pharmacokinetic, safety, tolerability, and efficacy profiles to Stelara, adhering to FDA biosimilar guidance. This marks the fifth FDA approval for an ustekinumab product, with Imuldosa anticipated to launch in the first half of 2025.

Dong-A ST receives FDA approval for Imuldosa, a biosimilar to Stelara, following a Phase 3 trial showing similarity in quality, safety, and efficacy. The approval marks Dong-A ST's second FDA-approved product, with Intas Pharmaceuticals set to commercialize it in the US and EU.

FDA approves Imuldosa, the fifth Stelara biosimilar for Crohn’s disease, ulcerative colitis, and other inflammatory conditions, expected to launch in early 2025.

Dong-A ST received FDA approval for Imuldosa, a Stelara biosimilar, amidst a crowded market of approved but unlaunched biosimilars. Stelara's sales are expected to decline post-2023 patent expiry, with biosimilars like Amgen's Wezlana and Samsung Bioepis's Pyzchiva set to launch in 2025. Stelara, an IL-12/IL-23 inhibitor, treats psoriatic arthritis, Crohn’s disease, plaque psoriasis, and ulcerative colitis.

Blue Shield of California will offer Idacio, an adalimumab biosimilar, at 75% less than Humira. This collaboration with Fresenius Kabi and Evio Pharmacy Solutions aims to reduce costs and improve access to biosimilars, with nearly all patients paying $0 out of pocket starting January 1, 2025.

Formycon AG and Fresenius Kabi received European Commission approval for FYB202/OTULFI™ (ustekinumab-aauz), a biosimilar to STELARA®, for treating Crohn’s disease, psoriasis, and psoriatic arthritis. Additionally, OTULFI™ received FDA approval for similar conditions, marking Fresenius Kabi’s fourth biosimilar in the U.S. market.